Search research articles
Contact Us
Filters
Showing results (81-90 of 120) with videos related to
Page
of 12
Sort By:
The American Journal of Cardiology
|
April 2, 2017
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II])
Benjamin A Steinberg, DaJuanicia N Simon, Laine Thomas, et al.
The Annals of Pharmacotherapy
|
December 20, 2014
Integrating electronic health records in the delivery of optimized anticoagulation therapy
Edith A Nutescu, Ann K Wittkowsky, Daniel M Witt, et al.
American Heart Journal
|
December 16, 2014
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Christopher B Granger, Renato D Lopes, Michael Hanna, et al.
American Heart Journal
|
November 9, 2016
How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Benjamin A Steinberg, Peter Shrader, Sunghee Kim, et al.
Circulation
|
December 16, 2014
Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Benjamin A Steinberg, Eric D Peterson, Sunghee Kim, et al.
Journal of the American Heart Association
|
December 24, 2017
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
Kevin L Thomas, Larry R Jackson, Peter Shrader, et al.
American Journal of Hematology
|
April 5, 2012
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
Scott Kaatz, Peter A Kouides, David A Garcia, et al.
Journal of the American College of Cardiology
|
December 17, 2016
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry
Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
American Heart Journal
|
September 11, 2013
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
David A Garcia, Lars Wallentin, Renato D Lopes, et al.
American Heart Journal
|
June 20, 2017
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 120) with videos related to
Sort By:
Page
of 12
The American Journal of Cardiology
|
April 2, 2017
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II])
Benjamin A Steinberg, DaJuanicia N Simon, Laine Thomas, et al.
The Annals of Pharmacotherapy
|
December 20, 2014
Integrating electronic health records in the delivery of optimized anticoagulation therapy
Edith A Nutescu, Ann K Wittkowsky, Daniel M Witt, et al.
American Heart Journal
|
December 16, 2014
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Christopher B Granger, Renato D Lopes, Michael Hanna, et al.
American Heart Journal
|
November 9, 2016
How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Benjamin A Steinberg, Peter Shrader, Sunghee Kim, et al.
Circulation
|
December 16, 2014
Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Benjamin A Steinberg, Eric D Peterson, Sunghee Kim, et al.
Journal of the American Heart Association
|
December 24, 2017
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
Kevin L Thomas, Larry R Jackson, Peter Shrader, et al.
American Journal of Hematology
|
April 5, 2012
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors
Scott Kaatz, Peter A Kouides, David A Garcia, et al.
Journal of the American College of Cardiology
|
December 17, 2016
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry
Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
American Heart Journal
|
September 11, 2013
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
David A Garcia, Lars Wallentin, Renato D Lopes, et al.
American Heart Journal
|
June 20, 2017
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Page
of 12